Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive versus postoperative ramosetron for prevention of postoperative nausea and vomiting after total knee arthroplasty
KCT0005080Phase 4Recruiting
- Sponsor
- SMG-SNU Boramae Medical Center
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ramosetron in postoperative nausea and vomiting (PONV), knee osteoarthritis (OA), sponsored by SMG-SNU Boramae Medical Center. Started May 2015; status: recruiting.
02
Drugs
ramosetron
03
Conditions
postoperative nausea and vomiting (PONV)knee osteoarthritis (OA)
Beyond the preview
Go deeper on KCT0005080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005080.